278 related articles for article (PubMed ID: 21292735)
1. ANCA vasculitis: time for a change in treatment paradigm? Not yet.
Ntatsaki E; Mooney J; Watts RA
Rheumatology (Oxford); 2011 Jun; 50(6):1019-24. PubMed ID: 21292735
[TBL] [Abstract][Full Text] [Related]
2. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
3. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
4. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
5. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for ANCA-associated vasculitides.
Guillevin L
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
[TBL] [Abstract][Full Text] [Related]
10. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
Rich EN; Brown KK
Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
12. L44. Management of relapses in vasculitis.
Mouthon L
Presse Med; 2013 Apr; 42(4 Pt 2):619-22. PubMed ID: 23477710
[No Abstract] [Full Text] [Related]
13. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA; Flores-Suárez LF
Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
[TBL] [Abstract][Full Text] [Related]
15. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
Hoffman GS
Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
[No Abstract] [Full Text] [Related]
16. [Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].
Dábague Guzmán J; Pedroza Granados J; Zúñiga Varga J
Reumatol Clin; 2011 Dec; 7 Suppl 3():S37-40. PubMed ID: 22119277
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Feb; 60(2):97-105. PubMed ID: 34622770
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment for vasculitis.
Jayne D
Clin J Am Soc Nephrol; 2010 Aug; 5(8):1359-62. PubMed ID: 20671223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
